Commercial Rights articles & resources on Made-in-China.com

Sunesis Pharmaceuticals Has Expanded Its Hematology Franchise

Jan 13, 2014

Sunesis Pharmaceuticals has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec, is for global commercial rights to SNS-062, a ...

Tags: Sunesis Pharmaceuticals, Medicine

OvaScience and Intrexon Corporation Have Announced an Agreement

Dec 23, 2013

OvaScience, a life sciences company, and Intrexon Corporation have announced an agreement to access Intrexon’s portfolio of technologies to accelerate the development of OvaScience’s OvaTure technology platform Separately, ...

Tags: OvaScience, Infertility Treatments

Summit Formes a Strategic Alliance with The University of Oxford to Develop New Treatments

Nov 27, 2013

UK-based drug discovery and development firm Summit has formed a strategic alliance with the University of Oxford in order to further strengthen its utrophin modulator program for the treatment of the fatal muscle wasting disease duchenne ...

Tags: Duchenne Muscular Dystrophy, Oxford University

PeptiDream and France-Based Ipsen Have Expanded Their Research Collaboration

Oct 9, 2013

Japanese pharmaceutical firm PeptiDream and France-based Ipsen have expanded their research collaboration and license option agreement signed in April 2013 to develop peptide drugs to treat serious endocrinologic disease. The deal has now ...

Tags: PeptiDream, Ipsen, peptide drugs

Ambrx and China-Based Zhejiang Medicine Collaborated to Develop and Commercialize ARX788

Jun 21, 2013

US-based Ambrx and China-based Zhejiang Medicine have collaborated to develop and commercialize ARX788, an antibody drug conjugate (ADC) targeting Her2-positive breast cancer. As per the deal, both the companies will advance the product ...

Tags: Ambrx, Medicine

Novozymes A/S Has Acquired Iogen Bio-Products

Feb 7, 2013

Novozymes A/S — a Denmark-based manufacturer of industrial enzymes and biotechnological solutions — has acquired Iogen Bio-Products — the industrial enzyme business of Ottawa-based biotechnology company Iogen Corp — ...

Tags: Novozymes, Iogen Bio-Products, Textile

Microsoft Launched The First Two of Its New Pay-as-You-Go Subscription Plans for Office

Feb 2, 2013

Microsoft this week launched the first two of its new pay-as-you-go subscription plans for Office. The company's rarely-shy CEO Steve Ballmer called the sales approach "an entirely new way to think about the productivity experience," and ...

Tags: Microsoft, Office 365, software

Novozymes Acquires Iogen Bio-Products

Feb 1, 2013

Novozymes acquires Iogen Bio-Products, industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 ...

Tags: Novozymes, Bio-Products, enzyme business

Grand Prix Is Costing Victorian Taxpayers More Than $30 Million for The Privilege

Jan 24, 2013

The Australian Formula One Grand Prix is costing Victorian taxpayers more than $30 million a year for the privilege of staging the annual race, according to an exclusive Herald Sun story today. The newspaper claims it has seen documents ...

Tags: Australia, Grand Prix, Licence Fee Costs

Arcadia Biosciences has signed an agreement with the CIMMYT and the US Agency

Nov 29, 2012

Arcadia Biosciences has signed an agreement with the International Maize and Wheat Improvement Center(CIMMYT)and the US Agency for International Development(USAID)to develop heat-tolerant wheat variants. The wheat varieties will be ...

Tags: CIMMYT, USAID, heat-tolerant, wheat variants

Orexo and Prostrakan Have Reconfigured The Commercial Rights to Abstral

Nov 29, 2012

Orexo and ProStrakan Group have reconfigured the commercial rights to the product, Abstral, in various territories worldwide. Abstral is the novel, rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl, and an ...

Tags: Abstral, Commercial Rights, oncology franchise

Daiichi Sankyo Has Signed an Exclusive Agreement with Coherus BioSciences

Nov 28, 2012

Daiichi Sankyo has signed an exclusive agreement with Coherus BioSciences to develop and commercialize biosimilar candidates in certain Asian countries including Japan. The collaboration will focus on the development, manufacturing and ...

Tags: Daiichi Sankyo, Coherus BioSciences, biosimilar candidates

Commercial Rights

Related Products